Procter & Gamble Pharmaceuticals, Inc. (P&GP), a division of The Procter & Gamble Company (NYSE: PG), has successfully developed and marketed a wide range of prescription products since the 1980s, including Actonel(R) (risedronate sodium) tablets, Asacol(R) (mesalamine) delayed-release tablets, Dantrium(R) (dantrolene sodium) capsules, Didronel(R) (etidronate disodium) tablets, Enablex(R) (darifenacin) extended release tablets and Macrobid(R) (nitrofurantoin monohydrate/macrocrystals) capsules. P&GP employs a Connect + Develop model for new product development through which it in-licenses or acquires 100 percent of its new drug development projects from biotech and pharmaceutical industry relationships. P&GP is committed to leveraging this model to build brands to address unmeet needs in the areas of gastrointestinal, musculoskeletal and women's health. The P&GP community consists of more than 3,000 employees working in over 22 countries worldwide. For more information on P&GP and its prescription product portfolio, please visit http://www.pgpharma.com.
Three billion times a day, P&G brands touch the lives of people around
the world. P&G has one of the strongest portfolios of trusted brands in
consumer health and wellness, including Align(R), Always(R), Crest(R),
Metamucil(R), Oral-B(R), Pepto-Bismol(R), Prilosec OTC(R), Scope(R),
Tampax(R) and Vicks(R), in addition to its leadership consumer brands,
including Ariel(R), Braun(R), Bounty(R), Charmin(R), Dawn(R), Downy(R),
Duracell(R), Folgers(R), Gillette(R), Head & Shoulders(R), Iams(R),
|SOURCE The Crohn's & Colitis Foundation of America|
Copyright©2008 PR Newswire.
All rights reserved